Arvinas Enters Material Definitive Agreement

NEW HAVEN, Conn., May 12, 2026 — Arvinas Inc. (ARVN) entered into a material definitive agreement, the company reported in an 8-K filing with the Securities and Exchange Commission.

The filing, submitted under Item 1.01, identifies the counterparty and contract type but does not disclose a dollar size. Item 7.01 covers Regulation FD disclosure while Item 9.01 lists financial statements and exhibits. The agreement affects Arvinas operations as a publicly traded biotechnology firm with a market focus on protein degradation therapeutics.

Prior to the filing the company operated without this specific contractual commitment. The new agreement takes effect immediately upon execution on or before the May 12 filing date. It replaces any prior state with defined performance obligations, payment terms if applicable, and termination conditions.

The change triggers multiple downstream requirements. Arvinas must monitor contractual milestones that could necessitate additional SEC filings such as a Form 8-K for material developments or amendments. Regulatory deadlines tied to the agreement may require disclosures to the Food and Drug Administration if the pact involves clinical supply or collaboration on pipeline candidates.

Counterparties to the agreement now hold enforceable rights that could lead to separate litigation or arbitration filings if performance thresholds are not met. Standard SEC rules require the company to furnish the full agreement as an exhibit, which becomes publicly accessible through the EDGAR system.

This marks the latest contractual disclosure by Arvinas in 2026. The company previously filed 8-K forms detailing collaboration adjustments and financing arrangements required under its public company reporting obligations established after its 2018 initial public offering.

The SEC mandates prompt disclosure of material definitive agreements to ensure investors receive timely notice of changes that could affect financial condition or operations.

The filing contains no Item 1.02 termination notice. Operational effect remains limited to the named agreement until further milestones are reached or additional disclosures are made.